Comparative Pharmacology
Head-to-head clinical analysis: INDO LEMMON versus RIMADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDO LEMMON versus RIMADYL.
INDO-LEMMON vs RIMADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammation, pain, and fever.
Selective cyclooxygenase-2 (COX-2) inhibitor, reducing prostaglandin synthesis involved in inflammation, pain, and fever.
Oral: 25-50 mg 2-3 times daily. Maximum daily dose: 200 mg.
50-100 mg orally twice daily, or 100-200 mg rectally once daily (suppository).
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life: 12–18 hours in dogs at recommended doses. Clinical context: Supports twice-daily dosing; longer half-life in some breeds may require dose adjustment.
Renal excretion of unchanged drug and metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for approximately 40%.
Primarily hepatic metabolism (oxidation, conjugation) with ~70% of metabolites excreted in urine and ~30% in feces via biliary elimination. Less than 5% excreted unchanged.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)